HC Wainwright Reaffirms “Buy” Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports.

Several other research analysts also recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Price Performance

YMAB opened at $9.77 on Wednesday. The firm has a market cap of $437.60 million, a P/E ratio of -18.09 and a beta of 0.61. Y-mAbs Therapeutics has a 1-year low of $6.09 and a 1-year high of $20.90. The company has a 50 day simple moving average of $12.96 and a two-hundred day simple moving average of $12.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same period in the previous year, the company earned ($0.18) EPS. Equities analysts anticipate that Y-mAbs Therapeutics will post -0.66 earnings per share for the current year.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the transaction, the insider now owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. The trade was a 30.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after purchasing an additional 613,175 shares in the last quarter. State Street Corp boosted its stake in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after buying an additional 405,169 shares in the last quarter. Squarepoint Ops LLC boosted its stake in Y-mAbs Therapeutics by 143.4% during the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after buying an additional 74,452 shares in the last quarter. Millennium Management LLC boosted its stake in Y-mAbs Therapeutics by 23.8% during the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after buying an additional 67,233 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after buying an additional 65,732 shares in the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.